lincomycin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antibiotics, produced by Streptomyces strains | 1582 | 154-21-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An antibiotic produced by Streptomyces lincolnensis var. lincolnensis. It has been used in the treatment of staphylococcal, streptococcal, and Bacteroides fragilis infections.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 1.80 | g | O |
| 1.80 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 50 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 30 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 129.94 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 25 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 1 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 2.10 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 5.60 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 29, 1964 | FDA | PHARMACIA AND UPJOHN |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug hypersensitivity | 239.31 | 65.54 | 68 | 120 | 310619 | 63178215 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug hypersensitivity | 162.16 | 49.64 | 48 | 139 | 298868 | 79445333 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J01FF02 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS Lincosamides |
| MeSH PA | D000900 | Anti-Bacterial Agents |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D011500 | Protein Synthesis Inhibitors |
| CHEBI has role | CHEBI:33281 | antibiotics |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Pneumococcal infectious disease | indication | 16814004 | |
| Staphylococcal infectious disease | indication | 56038003 | |
| Streptococcal infectious disease | indication | 85769006 | |
| Disorder of digestive system | contraindication | 53619000 | DOID:77 |
| Acute nephropathy | contraindication | 58574008 | |
| Hepatic failure | contraindication | 59927004 | |
| Colitis | contraindication | 64226004 | DOID:0060180 |
| Pseudomembranous enterocolitis | contraindication | 397683000 |
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Bees | Control of American foulbrood (Paenibacillus larvae) | Indication |
| Cats | Infections caused by gram-positive organisms (streptococci and staphylococci) | Indication |
| Chickens | Control of airsacculitis caused by Mycoplasma synoviae | Indication |
| Chickens | Control of airsacculitis caused by Mycoplasma gallisepticum | Indication |
| Chickens | Complicated chronic respiratory disease (air sac infection) | Indication |
| Chickens | Necrotic enteritis caused or complicated by Clostridium spp | Indication |
| Dogs | Infections caused by gram-positive organisms (streptococci and staphylococci) | Indication |
| Swine | Dysentery (bloody scours) | Indication |
| Swine | Infectious arthritis | Indication |
| Swine | Mycoplasma pneumonia | Indication |
| Swine | Proliferative enteropathies (ileitis) caused by Lawsonia intracellularis | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Lincocin Tablets | Zoetis Inc. | 1 |
| Lincocin, Lincomix 25 Injectable, Lincomix 50 Injectable, Lincomix 100 Injectable, Lincomix 300 Injectable | Zoetis Inc. | 1 |
| Lincocin Aquadrops | Zoetis Inc. | 1 |
| L-S 50 Water Soluble Powder | Zoetis Inc. | 2 |
| LINCOMIX 20, LINCOMIX 50 | Zoetis Inc. | 1 |
| LINCOMIX Soluble Powder | Zoetis Inc. | 1 |
| LINCOMIX and Banminth | Phibro Animal Health Corp. | 2 |
| LINCOMIX and Banminth | Zoetis Inc. | 2 |
| SAFE-GUARD plus LINCOMIX | Intervet Inc. | 2 |
| Stenorol and LINCOMIX | Huvepharma EOOD | 2 |
| Robenz and LINCOMIX | Zoetis Inc. | 2 |
| Deccox and LINCOMIX | Zoetis Inc. | 2 |
| Bio-Cox and LINCOMIX | Zoetis Inc. | 2 |
| COYDEN and LINCOMIX | Zoetis Inc. | 2 |
| Avatec and LINCOMIX | Zoetis Inc. | 2 |
| Zoamix and LINCOMIX | Zoetis Inc. | 2 |
| Coban and LINCOMIX | Zoetis Inc. | 2 |
| Lincomycin Soluble | Huvepharma EOOD | 1 |
| Linco Soluble | Zoetis Inc. | 1 |
| Lincosol Soluble Powder | Med-Pharmex Inc. | 1 |
| Lincomycin Injectable 30% | Zoetis Inc. | 1 |
| Lincomycin Hydrochloride Soluble Powder | Quo Vademus LLC | 1 |
| Lincomycin 100, Lincomycin 25, Lincomycin 300, Lincomycin Injection 100, Lincomycin Injection 25, Lincomycin Injection 300 | Sparhawk Laboratories Inc. | 1 |
| Lincomycin - Spectinomycin | Phibro Animal Health Corp. | 2 |
| Lincomycin Injectable, USP | Huvepharma EOOD | 1 |
| LincoMed 100, LincoMed 300 | Bimeda Animal Health Limited | 1 |
| LinxMed-SP | Bimeda Animal Health Limited | 1 |
| SpecLinx-50 | Bimeda Animal Health Limited | 2 |
| Lincomycin-Spectinomycin Water Soluble Powder | Huvepharma EOOD | 2 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 12.37 | acidic |
| pKa2 | 13.98 | acidic |
| pKa3 | 8.22 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| 50S ribosomal protein L10 | Ribosomal protein | WOMBAT-PK |
External reference:
| ID | Source |
|---|---|
| 4019802 | VUID |
| N0000147891 | NUI |
| D00223 | KEGG_DRUG |
| 4018090 | VANDF |
| 4019802 | VANDF |
| C0023726 | UMLSCUI |
| CHEBI:6472 | CHEBI |
| 3QB | PDB_CHEM_ID |
| CHEMBL1447 | ChEMBL_ID |
| D008034 | MESH_DESCRIPTOR_UI |
| DB01627 | DRUGBANK_ID |
| 3000540 | PUBCHEM_CID |
| 10941 | IUPHAR_LIGAND_ID |
| 1419 | INN_ID |
| 7179-49-9 | SECONDARY_CAS_RN |
| BOD072YW0F | UNII |
| 6398 | RXNORM |
| 1950 | MMSL |
| 4979 | MMSL |
| 4980 | MMSL |
| 7112 | MMSL |
| d00279 | MMSL |
| 002793 | NDDF |
| 004867 | NDDF |
| 18449009 | SNOMEDCT_US |
| 2596005 | SNOMEDCT_US |
| 372677003 | SNOMEDCT_US |
| CHEMBL3989551 | ChEMBL_ID |
| CHEMBL1201097 | ChEMBL_ID |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Lincocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-0104 | INJECTION, SOLUTION | 300 mg | INTRAMUSCULAR | NDA | 27 sections |
| Lincocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-0104 | INJECTION, SOLUTION | 300 mg | INTRAMUSCULAR | NDA | 27 sections |
| Lincocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-0104 | INJECTION, SOLUTION | 300 mg | INTRAMUSCULAR | NDA | 27 sections |
| Lincocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-0104 | INJECTION, SOLUTION | 300 mg | INTRAMUSCULAR | NDA | 27 sections |
| Lincocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-0107 | INJECTION, SOLUTION | 300 mg | INTRAMUSCULAR | NDA | 27 sections |
| Lincocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-0107 | INJECTION, SOLUTION | 300 mg | INTRAMUSCULAR | NDA | 27 sections |
| Lincocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-0107 | INJECTION, SOLUTION | 300 mg | INTRAMUSCULAR | NDA | 27 sections |
| Lincocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-0107 | INJECTION, SOLUTION | 300 mg | INTRAMUSCULAR | NDA | 27 sections |
| Lincocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-0555 | INJECTION, SOLUTION | 300 mg | INTRAMUSCULAR | NDA | 27 sections |
| Lincocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-0555 | INJECTION, SOLUTION | 300 mg | INTRAMUSCULAR | NDA | 27 sections |
| Lincocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-0555 | INJECTION, SOLUTION | 300 mg | INTRAMUSCULAR | NDA | 27 sections |
| Lincocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-0555 | INJECTION, SOLUTION | 300 mg | INTRAMUSCULAR | NDA | 27 sections |
| LINCOMYCIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0404-9901 | INJECTION, SOLUTION | 300 mg | INTRAMUSCULAR | ANDA | 14 sections |
| LINCOMYCIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0404-9901 | INJECTION, SOLUTION | 300 mg | INTRAMUSCULAR | ANDA | 14 sections |
| LINCOMYCIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0404-9901 | INJECTION, SOLUTION | 300 mg | INTRAMUSCULAR | ANDA | 14 sections |
| Lincomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-193 | INJECTION, SOLUTION | 300 mg | INTRAVENOUS | ANDA | 28 sections |
| Lincomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 39822-0350 | INJECTION, SOLUTION | 300 mg | INTRAMUSCULAR | ANDA | 27 sections |
| Lincomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 39822-0350 | INJECTION, SOLUTION | 300 mg | INTRAMUSCULAR | ANDA | 27 sections |
| Lincomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 39822-0353 | INJECTION, SOLUTION | 300 mg | INTRAMUSCULAR | ANDA | 27 sections |
| Lincomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 39822-0353 | INJECTION, SOLUTION | 300 mg | INTRAMUSCULAR | ANDA | 27 sections |
| Lincomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42571-374 | INJECTION, SOLUTION | 300 mg | INTRAVENOUS | ANDA | 22 sections |
| Lincomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42571-374 | INJECTION, SOLUTION | 300 mg | INTRAVENOUS | ANDA | 22 sections |
| Lincomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-4533 | INJECTION, SOLUTION | 300 mg | INTRAMUSCULAR | ANDA | 28 sections |
| Lincomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-4533 | INJECTION, SOLUTION | 300 mg | INTRAMUSCULAR | ANDA | 28 sections |
| LINCOMYCIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52584-353 | INJECTION, SOLUTION | 300 mg | INTRAMUSCULAR | ANDA | 14 sections |
| lincomycin hydrochloride | Human Prescription Drug Label | 1 | 68083-478 | INJECTION, SOLUTION | 300 mg | INTRAMUSCULAR | ANDA | 22 sections |
| Lincomycin hydrochloride | Human Prescription Drug Label | 1 | 68083-479 | INJECTION, SOLUTION | 300 mg | INTRAMUSCULAR | ANDA | 22 sections |
| lincomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70436-034 | INJECTION, SOLUTION | 300 mg | INTRAVENOUS | ANDA | 25 sections |
| lincomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70436-035 | INJECTION, SOLUTION | 300 mg | INTRAVENOUS | ANDA | 25 sections |
| Lincomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70625-113 | INJECTION, SOLUTION | 300 mg | INTRAMUSCULAR | ANDA | 27 sections |